Liver Diseases  >>  SIR-Spheres (yttrium-90 microspheres)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
SIRTACE, NCT00867750 / 2006-006478-79: SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation in Patients With Unresectable Hepatocellular Carcinoma

Completed
2
28
Europe
Radioembolisation (SIR-Spheres® microspheres), Transarterial Chemoembolisation
Sirtex Medical
Hepatocellular Carcinoma
06/11
06/11
EXPLOSIVE, NCT01186263 / 2008-005609-21: Predictive Value of 99mTc- Albumin Spheres Before 90Y- SIR Therapy

Completed
2
24
Europe
MAA for diagnostic SPECT imaging, TechneScan Lyo MAA, Diagnostic B20- SPECT imaging., ROTOP HSA microspheres B20
University of Magdeburg, Sirtex Medical
Colorectal Cancer, Liver Metastases
07/11
08/13
NCT00712790: Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC)

Checkmark hepatocellular carcinoma
Mar 2014 - Mar 2014: hepatocellular carcinoma
Checkmark P1/2 data
Sep 2011 - Sep 2011: P1/2 data
Completed
1/2
35
RoW
Sorafenib, BAY 43-9006, SIR-Spheres, Yttrium-90 Microspheres
Singapore Clinical Research Institute, National Medical Research Council (NMRC), Singapore, Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma, Sirtex Medical
Hepatocellular Carcinoma
06/09
04/14

Download Options